Next Generation News and Research

RSS

Kopin second-quarter total sales increase 7.0% to $30.2 million

Kopin Corporation today announced financial results for the second quarter ended June 26, 2010.

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

MannKind second-quarter total operating expenses decrease to $16.0 million

MannKind Corporation today reported financial results for the second quarter ended June 30, 2010.

2 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

30 Jul 2010

Researchers identify genetic mutation for Uner Tan Syndrome

A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche. The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery.

30 Jul 2010

Life Technologies second-quarter Non-GAAP revenue increases 8% to $906 million

Life Technologies Corporation today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

30 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

Transcend Services second-quarter 2010 revenue increases 31% to $22,209,000

TRANSCEND SERVICES, INC., a leading provider of clinical documentation services to the U.S. healthcare market, today announced its unaudited financial results for the second quarter ended June 30, 2010.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid.

29 Jul 2010

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

NDS Surgical Imaging (NDSsi) today launched its next-generation visualization and informatics platform—the ConnectOR G2—with production units now shipping to customers. Based on the NDSsi technology vision of Medical Visualization Informatics (MVI), ConnectOR G2 medical-grade products are leading the industry in procedural efficacy by offering the unique ability to connect the realms of PACS imaging, surgical video and medical informatics.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Viking Systems extends supply contract with Boston Scientific

Viking Systems, Inc. announced today an extension of its supply contract with Boston Scientific. Based on the continued success of Boston Scientific's SpyGlass Direct Visualization System, the companies agreed to extend the term of the supply agreement through May 2012.

28 Jul 2010

Water Pik launches advertising campaign to introduce consumers to new Waterpik Water Flosser

Water Pik, Inc., a leading developer and manufacturer of innovative personal healthcare products, today announced the launch of the "Say No To String" advertising campaign to introduce consumers to the new Waterpik Water Flosser and to promote it as an easier and more effective alternative to traditional string floss.

28 Jul 2010

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2808 at the AACC/CSCC 2010 Clinical Lab Expo here, July 27-29 – and it's giving them a unique way to see firsthand where their own "dream lab" might take them.

From Roche Sequencing and Life Science 28 Jul 2010

Scientists unveil nanoparticle for photoacoustic imaging

Spotting a single cancerous cell that has broken free from a tumor and is traveling through the bloodstream to colonize a new organ might seem like finding a needle in a haystack. But a new imaging technique from the University of Washington is a first step toward making this possible.UW researchers have developed a multifunctional nanoparticle that eliminates the background noise, enabling a more precise form of medical imaging - essentially erasing the haystack, so the needle shines through. A successful demonstration with photoacoustic imaging was reported today (July 27) in the journal Nature Communications.

28 Jul 2010

BioImagene collaborates with ten new academic medical centers to develop digital pathology solutions

BioImagene, Inc., the leading provider of innovative digital pathology solutions has added ten new academic medical centers to its roster of collaborators during the last quarter. Many of these collaborators have been named "America's Best Hospitals 2010-2011: The Honor Roll" by U.S. News and World Report.

28 Jul 2010

IntriCon second-quarter net sales increase 16.6% to $14.9 million

IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its second quarter ended June 30, 2010.

28 Jul 2010